Becton Dickinson and Co (BDX) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its stake in Becton Dickinson and Co (NYSE:BDX) by 21.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,472 shares of the medical instruments supplier’s stock after purchasing an additional 18,638 shares during the period. Nisa Investment Advisors LLC’s holdings in Becton Dickinson and were worth $23,004,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the last quarter. Harfst & Associates Inc. increased its position in shares of Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd increased its position in shares of Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares during the last quarter. Acrospire Investment Management LLC increased its position in shares of Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 600 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in shares of Becton Dickinson and in the third quarter worth approximately $191,000. Institutional investors own 75.53% of the company’s stock.

Several research analysts recently weighed in on BDX shares. Wells Fargo & Co started coverage on shares of Becton Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price objective on the stock. Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Royal Bank of Canada reiterated a “hold” rating and set a $210.00 price target on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley increased their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price target on shares of Becton Dickinson and in a research report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $230.20.

Shares of Becton Dickinson and Co (NYSE:BDX) traded up $1.26 during midday trading on Friday, reaching $225.82. 1,554,900 shares of the company’s stock were exchanged, compared to its average volume of 1,643,650. Becton Dickinson and Co has a twelve month low of $169.19 and a twelve month high of $229.68. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The company has a market capitalization of $52,060.00, a PE ratio of 48.56, a P/E/G ratio of 1.70 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period last year, the business earned $2.12 earnings per share. sell-side analysts forecast that Becton Dickinson and Co will post 10.89 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date was Thursday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio is 64.52%.

WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/becton-dickinson-and-co-bdx-shares-bought-by-nisa-investment-advisors-llc.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply